The Conversation (0)
Life Science Big News Roundup: Algernon’s NP-120 Outperforms Merck’s Phase 3 Drug MK-7264 by 110 Percent; Naturally Splendid’s Natera Sport(TM) Bites at Genesis PGA Tournament
Dec. 06, 2019 10:00AM PST
Life Science Investing News
In case you missed it, here is this week’s life science big news roundup.
In case you missed it, here is this week’s life science big news roundup:
Biotech:
- Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110 Percent
- Naturally Splendid’s Natera Sport(TM) Bites at Genesis Invitational PGA Tournament
To see our previous Life Science Investing Big News Roundups, please click here.